◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › C › CGC

Canopy Growth Corp (CGC) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-10-02

Canopy Growth Corp (CGC) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Smiths Falls, Canada with about 1,128 employees. Its market capitalization is roughly $293 million. In the fiscal year ended 2026-03-31, CGC reported C$285M in revenue and (C$263M) in net income.

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.

Interactive charts & full statements → Open the CGC valuation workbench →

CGC Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31	2016-03-31	2015-03-31	2014-12-31	2014-03-31	2013-03-31	2012-03-31	2011-03-31	2010-03-31
Total Revenue	C$321M	C$285M	C$269M	C$297M	C$333M	C$476M	C$547M	C$399M	C$226M	C$78M	C$40M	C$13M	C$2M	C$1M	—	C$0M	C$0M	C$0M	C$0M
Gross Profit	C$82M	C$70M	C$80M	C$81M	(C$64M)	(C$187M)	C$67M	(C$32M)	C$89M	C$74M	C$39M	C$19M	C$0M	C$0M	—	C$0M	—	C$0M	C$0M
Gross Margin %	25.5%	24.5%	29.6%	27.2%	-19.1%	-39.4%	12.2%	-8.0%	39.3%	95.2%	97.0%	149.5%	21.8%	36.2%	—	100.0%	—	100.0%	100.0%
Operating Income (EBIT)	(C$103M)	(C$73M)	(C$117M)	(C$229M)	(C$2.6B)	(C$1.0B)	(C$1.2B)	(C$1.7B)	(C$615M)	(C$108M)	(C$14M)	(C$3M)	(C$7M)	(C$7M)	(C$1M)	C$0M	C$0M	C$0M	C$0M
Operating Margin %	-31.9%	-25.7%	-43.5%	-77.0%	-789.3%	-214.2%	-227.5%	-418.5%	-271.8%	-138.3%	-35.3%	-21.6%	-346.1%	-588.0%	—	-1559.1%	-449.2%	-436.3%	-4903.1%
Net Income	(C$259M)	(C$263M)	(C$598M)	(C$657M)	(C$3.3B)	(C$310M)	(C$1.7B)	(C$1.3B)	(C$736M)	(C$67M)	(C$8M)	(C$3M)	(C$9M)	(C$9M)	(C$1M)	C$0M	C$0M	C$0M	C$0M
Net Margin %	-80.7%	-92.4%	-222.3%	-221.2%	-983.7%	-65.2%	-319.2%	-331.3%	-325.3%	-86.3%	-18.9%	-27.5%	-470.9%	-779.6%	—	-1559.1%	-449.2%	-536.3%	-4903.1%
EBITDA	(C$188M)	(C$188M)	(C$479M)	(C$313M)	(C$2.9B)	(C$53M)	(C$450M)	(C$1.4B)	(C$567M)	(C$96M)	(C$1M)	C$1M	(C$6M)	—	(C$1M)	C$0M	C$0M	C$0M	C$0M
Earnings Per Share (EPS)	C$-0.70	C$-0.09	C$-5.56	C$-8.79	C$-70.69	C$-0.82	C$-4.64	C$-3.71	C$-2.18	C$-0.38	C$-0.06	C$-0.05	C$-0.30	—	C$-0.93	C$-0.06	C$-0.02	C$-0.02	C$-0.03
Shares Outstanding (M)	422M	—	108M	75M	46M	—	376M	356M	338M	177M	119M	77M	—	—	1M	1M	1M	1M	1M

CAD; C$M / C$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CGC Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	C$81M	C$71M	C$102M	C$67M	C$72M	C$65M	C$75M	C$63M
Gross Profit	C$22M	C$8M	C$29M	C$22M	C$18M	C$11M	C$24M	C$22M
Gross Margin %	27.4%	11.6%	28.8%	32.9%	25.0%	16.2%	32.2%	34.7%
Operating Income (EBIT)	(C$22M)	(C$27M)	(C$36M)	(C$17M)	(C$23M)	(C$4M)	(C$24M)	(C$46M)
Operating Margin %	-27.2%	-38.6%	-35.4%	-25.3%	-31.4%	-6.8%	-31.9%	-72.9%
Net Income	(C$15M)	(C$157M)	(C$86M)	(C$2M)	(C$42M)	(C$221M)	(C$122M)	(C$128M)
Net Margin %	-18.0%	-220.5%	-84.0%	-2.5%	-57.6%	-339.5%	-163.1%	-203.7%
EBITDA	(C$5M)	(C$137M)	(C$63M)	C$17M	(C$22M)	(C$194M)	(C$94M)	(C$100M)
Earnings Per Share (EPS)	C$-0.03	C$-0.41	C$-0.25	C$-0.01	C$-0.22	C$-2.05	C$-1.11	C$-1.48
Shares Outstanding (M)	422M	385M	346M	274M	188M	108M	110M	87M

CAD; C$M / C$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CGC Free Cash Flow History

Cash flow	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31	2016-03-31	2015-03-31	2014-12-31	2014-03-31	2013-03-31	2012-03-31	2011-03-31	2010-03-31
Cash from Operations (CFO)	(C$78M)	(C$64M)	(C$166M)	(C$282M)	(C$558M)	(C$546M)	(C$466M)	(C$773M)	(C$535M)	(C$82M)	(C$27M)	(C$12M)	(C$10M)	(C$10M)	(C$1M)	C$0M	C$0M	C$0M	C$0M
Capital Expenditures (CapEx)	C$5M	C$6M	C$11M	C$4M	C$10M	C$48M	C$174M	C$722M	C$719M	C$178M	C$30M	C$11M	C$12M	C$11M	C$1M	C$0M	C$0M	C$0M	C$0M
Free Cash Flow (FCF)	(C$84M)	(C$70M)	(C$177M)	(C$286M)	(C$568M)	(C$594M)	(C$640M)	(C$1.5B)	(C$1.3B)	(C$260M)	(C$57M)	(C$23M)	(C$22M)	(C$21M)	(C$2M)	C$0M	C$0M	C$0M	C$0M
FCF Margin %	-26.0%	-24.5%	-65.8%	-96.2%	-170.4%	-124.8%	-117.1%	-374.8%	-554.0%	-333.0%	-141.9%	-182.4%	-1144.6%	-1830.2%	—	-892.8%	-391.6%	-633.0%	-1274.5%

CAD; C$M / C$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CGC Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	(C$25M)	(C$18M)	(C$17M)	(C$18M)	(C$10M)	(C$33M)	(C$27M)	(C$54M)
Capital Expenditures (CapEx)	C$1M	C$1M	C$2M	C$1M	C$1M	C$3M	C$2M	C$3M
Free Cash Flow (FCF)	(C$26M)	(C$19M)	(C$19M)	(C$19M)	(C$12M)	(C$36M)	(C$29M)	(C$56M)
FCF Margin %	-31.7%	-27.2%	-18.7%	-29.2%	-16.4%	-55.8%	-38.2%	-89.6%

CAD; C$M / C$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CGC Balance Sheet History

Balance sheet	2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31	2016-03-31	2015-03-31	2014-12-31	2014-03-31	2013-03-31	2012-03-31	2011-03-31	2010-03-31
Total Assets	C$1.1B	C$1.1B	C$918M	C$1.3B	C$2.4B	C$5.6B	C$6.8B	C$4.8B	C$8.7B	C$1.4B	C$678M	C$143M	C$48M	C$26M	C$5M	C$1M	C$1M	C$1M	C$1M
Cash & Cash Equivalents	C$337M	C$365M	C$114M	C$170M	C$668M	C$776M	C$1.2B	C$916M	C$2.5B	C$323M	C$102M	C$15M	C$21M	C$6M	C$2M	C$0M	C$0M	C$0M	C$0M
Total Liabilities	C$415M	C$421M	C$430M	C$800M	C$1.7B	C$2.0B	C$3.2B	C$1.2B	C$1.5B	C$194M	C$63M	C$20M	C$6M	C$4M	C$1M	C$0M	C$0M	C$0M	C$0M
Total Debt (Short + Long-Term)	C$254M	C$248M	C$321M	C$612M	C$1.3B	C$1.5B	C$1.6B	C$489M	C$946M	C$8M	C$10M	C$4M	C$2M	C$3M	C$0M	C$0M	C$0M	C$0M	C$0M
Total Shareholders' Equity	C$689M	C$698M	C$487M	C$500M	C$758M	C$3.6B	C$3.5B	C$3.4B	C$6.8B	C$1.2B	C$640M	C$124M	C$41M	C$22M	C$4M	C$0M	C$1M	C$1M	C$1M

CAD; C$M / C$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CGC viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

EOLS · Evolus Inc — $487 million
TKNO · Alpha Teknova Inc — $454 million
KMDA · Kamada — $444 million
TLRY · Tilray Inc — $392 million
BIOA · BioAge Labs, Inc — $269 million
GLAS · Glass House Brands Inc. — $221 million
TAK · Takeda Pharmaceutical Co Ltd ADR — $66 billion
UTHR · United Therapeutics Corporation — $26 billion

← CGBL All “C” companies CGCB →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.